2. Sadock BJ, Ruiz P, Sadock VA, Kaplan HI. Kaplan & Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2015.
3. Korean Neuropsychiatric Association. Textbook of neuropsychiatry. 3th ed. Seoul: IMis Company; 2017.
4. Na KS, Lee SI. Effect of methylphenidate on learning in normal population. J Korean Acad Child Adolesc Psychiatry 2012;23:49-56.
5. Choi JH, Lee SM. Safety issues in neuroenhancement. Korean J Med Ethics 2014;17:349-362.
6. Schmidt A, Müller F, Dolder PC, Schmid Y, Zanchi D, Egloff L, Liechti ME, Borgwardt S. Acute effects of methylphenidate, modafinil, and MDMA on negative emotion processing. Int J Neuropsychopharmacol 2018;21:345-354.
8. Park JA, Jang HS, Jeong SH, Ha JH, Lee H, Lee MG. Effect of modafinil and methylphenidate on sleep-wake architecture and EEG power spectra in rats. Korean J Psychopharmacol 2009;20:181-193.
9. Kim DS. Studies on application of psychoactive drugs for relieving of combat fatigue. J Korea Inst Mil Sci Technol 2010;13:689-698.
10. Borghol A, Aucoin M, Onor I, Jamero D, Hawawini F. Modafinil for the improvement of patient outcomes following traumatic brain injury. Innov Clin Neurosci 2018;15:17-23.
11. Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage 2011;41:761-767.
12. Dalal S, Melzack R. Potentiation of opioid analgesia by psychostimulant drugs: a review. J Pain Symptom Manage 1998;16:245-253.
13. Abikoff H, Hechtman L, Klein RG, Weiss G, Fleiss K, Etcovitch J, Cousins L, Greenfield B, Martin D, Pollack S. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004;43:802-811.
14. Yoo HJ, Yang SJ, Shin D, Kang H, Kim BN, Kim JH, Ahn D, Yoo HK, Cheon KA, Hong H. The Korean practice parameter for the treatment of attention-deficit hyperactivity disorder(III): pharmacologic treatment. J Korean Acad Child Adolesc Psychiatry 2007;18:16-25.
15. Park JP, Lee JI, Jhin HK, Min HJ, Hwang JW, Kim Y. Clinical characteristics of methylphenidate use in Korean children and adolescents with autism spectrum disorder: a retrospective study. J Korean Acad Child Adolesc Psychiatry 2012;23:154-160.
16. Westfall TC, Westfall DP. Adrenergic agonsists and antagonists. In: Brunton LL, Lazo JS, Parker KL, editor. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2011. p. 299-300.
17. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006;60:1111-1120.
19. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006;160:82-90.
20. Korean College of Neuropsychopharmacology. Clinical neuropsycho pharmacology. Seoul: Sigma Press; 2014.
21. Koo YJ, Lee MS, Shin DW, Kim EJ, Kang JW, Cho SC. Neurobiology of attention-deficit/hyperactivity disorder and the action mechanism of OROS methylphenidate. J Korean Acad Child Adolesc Psychiatry 2012;23:Suppl. S5-S11.
22. Kim HW, Ko BJ, Park TW, Shin YO, Lee JS, Chung US, Cho IH, Choi TY, Bahn GH. Safety and tolerability of OROS methylphenidate for the treatment of ADHD. J Korean Acad Child Adolesc Psychiatry 2012;23:Suppl. S24-S45.
23. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:695-700.
24. Hwang JW. Non-stimulant medications in the treatment of attention-deficit hyperactivity disorder. J Korean Acad Child Adolesc Psychiatry 2008;19:72-82.
25. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs 2008;68:1803-1839.
28. Federici M, Latagliata EC, Rizzo FR, Ledonne A, Gu HH, Romigi A, Nistico R, Puglisi-Allegra S, Mercuri NB. Electrophysiological and amperometric evidence that modafinil blocks the dopamine uptake transporter to induce behavioral activation. Neuroscience 2013;252:118-124.
29. US Food and Drug Administration. Modafinil (marketed as Provigil): serious skin reactions. Rockville: US Food and Drug Administration; 2007.
30. Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: national findings. Rockville: Department of Health and Human Services; 2008.
31. Bright GM. Abuse of medications employed for the treatment of ADHD: results from a large-scale community survey. Medscape J Med 2008;10:111.
32. Repantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010;62:187-206.
33. Goncalves J, Baptista S, Silva AP. Psychostimulants and brain dysfunction: a review of the relevant neurotoxic effects. Neuropharmacology 2014;87:135-149.